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Abstract
Autism is a complex disease whose etiology remains elusive. We
integrated previously and newly generated data and developed a
systems framework involving the interactome, gene expression and
genome sequencing to identify a protein interaction module with
members strongly enriched for autism candidate genes. Sequencing
of 25 patients confirmed the involvement of this module in autism,
which was subsequently validated using an independent cohort of
over 500 patients. Expression of this module was dichotomized with
a ubiquitously expressed subcomponent and another subcomponent
preferentially expressed in the corpus callosum, which was
significantly affected by our identified mutations in the network
center. RNA-sequencing of the corpus callosum from patients with
autism exhibited extensive gene mis-expression in this module, and
our immunochemical analysis showed that the human corpus
callosum is predominantly populated by oligodendrocyte cells.
Analysis of functional genomic data further revealed a significant
involvement of this module in the development of oligodendrocyte
cells in mouse brain. Our analysis delineates a natural network
involved in autism, helps uncover novel candidate genes for this
disease and improves our understanding of its molecular pathology.
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Introduction
Genetic studies of autism spectrum disorders (ASDs) in the past
decade have implicated a large number of clinical mutations in more
than 300 different human genes (Basu et al, 2009). These mutations
account for very few autism cases, suggesting that the genetic archi-
tecture of autism is comprised of extreme locus heterogeneity
(Abrahams & Geschwind, 2008). Key issues in understanding the
underlying pathophysiology of ASDs are identifying and characteriz-
ing the shared molecular pathways perturbed by the diverse set of
ASD mutations (Bill & Geschwind, 2009; Berg & Geschwind, 2012).
The common approach to uncover pathways underlying ASD is
based on enrichment tests against a set of annotated pathways for
mutations derived from a genome-wide comparison between cases
and controls. For example, a b-catenin/chromatin remodeling
protein network showed enrichment for the de novo mutations iden-
tified from sequencing exomes of sporadic cases with autism
(O’Roak et al, 2012). Common variants from genome-wide associa-
tion studies (GWAS) were also tested against KEGG pathways,
suggesting a possible association with a pathway for ketone body
metabolism (Yaspan et al, 2011). However, in spite of extensive
efforts by many research groups worldwide, including recent large-
scale genotyping and sequencing studies (Anney et al, 2012; Liu
et al, 2013), we still lack a complete understanding of the genetic
underpinnings of this disease. Therefore, instead of searching
genome-wide, we decided that a focused study either by injecting
our prior knowledge or by utilizing information from molecular
studies of natural pathways might help discover pathways relevant
to ASD etiology. Gilmen et al constructed a network by connecting
every pair of genes with any functional association, such as shared
annotation terms, pathway memberships, interacting partners or co-
evolutionary patterns. This association network was then seeded
with the genes previously found in ASD-associated de novo copy
number variants (CNVs) followed by a search of their neighbor-
hoods for sub-networks most enriched for these affected genes. This
“seeding-and-expansion” strategy identified functionally associated
genes in synapse development, axon targeting and neuron motility
(Gilman et al, 2011). Related studies were focused on a set of
proteins potentially implicated in ASD and characterized their inter-
acting partners to identify molecular pathways underlying ASD
(Sakai et al, 2011; Corominas et al, 2014; Cristino et al, 2014).
These approaches all started with a set of previously curated
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ASD-associated genes, which served to define an ASD-related
framework. However, given our incomplete understanding of ASD,
identifying ASD-associated pathways purely based on these known
genes might not be able to reveal the “natural” organization of
genes implicated in this disease and may miss many components
involved in ASD.
A complementary approach was also developed recently, in
which human genes were first grouped based on their expression
profiles across brain developmental stages or anatomical brain
sections. Significant mutation or aberrant expression within a few
co-expressed gene groups should then reveal a more complete func-
tional organization underlying ASD (Voineagu et al, 2011; Ben-
David & Shifman, 2012; Parikshak et al, 2013; Willsey et al, 2013).
However, co-expression analysis often identifies a large number of
genes co-expressed for many reasons, including gene sub-cellular
co-localization, co-evolution or just coincidental expression, and
thus, it is not possible to infer the exact physical organization of
genes in ASD from such a heterogeneous co-expression network.
For example, when we considered a threshold of Pearson’s correla-
tion of 0.7 for genes expressed across brain anatomical sections
(Hawrylycz et al, 2012), more than 2.8 million gene pairs displayed
significant co-expression, whereas the complete physical interac-
tome in human is estimated to consist of 150k to 370k protein–
protein interactions (Hart et al, 2006), accounting for only ~5–10%
of the co-expressed genes. Therefore, co-expression analyses reveal
functional association between genes, but not “physical” organiza-
tion; however, the latter is crucial for delineating the mechanistic
basis of the disease.
Herein, we describe a systems biology approach (Supplementary
Fig S1) to unravel natural organization of physically interacting
proteins implicated in ASD. We analyzed the human protein interac-
tome to detect a protein module strongly enriched for biological
processes relevant to ASD etiology. The module is frequently
mutated in patients with autism, which was further validated in a
large patient cohort and by our own independent sequencing stud-
ies. Network and transcriptome analyses of this ASD module collec-
tively revealed that the corpus callosum is likely a potential tissue of
origin underlying ASD, in line with its morphological alterations
that have been described in patients with ASD (Boger-Megiddo et al,
2006; Frazier et al, 2012).
Results
Modularization of the human protein interactome
We first generated a new topological protein interaction network
using the most comprehensive human protein interactome from
BioGrid (Stark et al, 2011) comprising 13,039 proteins and 69,113
curated interactions (see Materials and Methods, and Supplemen-
tary Dataset S1). Since interacting proteins are presumably co-
expressed, the quality of these protein interactions was often
analyzed by co-expression analysis (Yu et al, 2008). We found
significantly increased gene co-expression from this dataset relative
to a set of previously benchmarked interacting proteins (Das & Yu,
2012) and also to randomly paired proteins (Supplementary Fig S2,
and also see Materials and Methods, P < 1e-10, Wilcoxon rank-sum
test), demonstrating high quality of this human protein interactome
dataset. We then topologically clustered the proteins that consti-
tuted the network into highly interacting modules using a parame-
ter-free algorithm (Materials and Methods) that was specifically
designed for detecting community structures in a large-scale
network (Blondel et al, 2008). By maximizing the score for network
modularity, the human interactome was decomposed into 817 topo-
logical modules (Fig 1, Supplementary Dataset S1) of non-uniform
sizes (Supplementary Fig S3A). Within each module, the proteins
tightly interacted with each other, but sparsely with proteins in
other modules. This observed modularity of the human interactome
was then tested against a set of shuffled networks of the same size
by randomly rewiring existing interactions while maintaining the
same number of interacting partners. None of the randomized
networks achieved the same modularity observed from the network
in this study (Supplementary Fig S3B), confirming the significance
of these topological clusters (P < 0.01, estimated from the 100
random shufflings).
Gene Ontology (GO) enrichment analysis for the 192 topological
modules containing more than five genes (Supplementary Fig S4)
revealed 85 modules that showed significant enrichment for at least
one GO term (FDR < 0.05, hypergeometric test, Supplementary
Dataset S2). The enrichment was highly significant for most of the
modules (FDR ≤ 5e-3, Supplementary Fig S4), including module #22
for histone acetylation (FDR = 5.3e-3), module #4 for kinase
cascades (FDR = 9.41231e-18), module #2 for DNA-dependent regu-
lation (FDR = 2.43e-237) and module #13 for synaptic transmission
(FDR = 2.77e-28). Overall, these observations revealed the modular
architecture of the human protein interactome, with different
modules organized for specific functions (Supplementary Fig S5).
A protein interaction module is associated with autism
To determine whether any of the modules are related to autism, we
first examined the 383 genes involved in ASD susceptibility from the
SFARI Gene list (https://gene.sfari.org/autdb/) that were present in
the network. Enrichment tests for each module in the network
revealed that module #2 (1,430 member genes, FDR = 2.3e-3,
hypergeometric test) and #13 (119 member genes, FDR = 4.6e-11,
hypergeometric test) showed significant enrichment. Module #2 was
enriched for transcriptional regulation, including ASD-associated
transcription factors and chromatin remodelers (FOXP2, MECP2, and
CHD8, etc.), and module #13 encompassed many genes for synaptic
transmission (SHANK2, SHANK3, NLGN1, NLGN3, etc., see GO
enrichment test above and also in Supplementary Fig S6). Given the
substantially stronger enrichment for SFARI ASD genes in module #13
relative to module #2, in the remaining part of the study, we focused
on module #13 for its ASD implication and molecular function.
To determine that the observed enrichment for SFARI genes was
not biased by unequal CDS (coding DNA sequences) length and GC
content in the above comparison, we further performed 10,000 sets
of permutation tests. In each permutation, we randomly sampled
genes with indistinguishable CDS length and GC content from the
SFARI genes (see Materials and Methods), and we validated the
enrichment for SFARI genes in module #13 (P < 1e-5). The SFARI
reference ASD gene list, although comprehensive, is likely to have
potential curation bias. We therefore tested this module’s enrich-
ment for ASD candidate genes using a variety of validation tests.
We first tested whether the observed enrichment for ASD genes in
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module #13 was simply accounted for by its overall enrichment for
synaptic genes. Of the total 1,886 known synaptic genes from
SynaptomeDB (Pirooznia et al, 2012), 1,745 were present on the
network. After removal of the synaptic genes from module #13, ASD
non-synaptic genes were highly enriched in the module relative to
those in the entire network or across the genome (14.8% versus
2.6% and 2.9%, respectively; P ≤ 1.64e-4, hypergeometric test).
Furthermore, 5.44% (95/1745) of the ASD SFARI genes were in the
synaptic set for the entire network, but 21% (25/119) were in
module #13, a highly significant enrichment (P = 3.28e-8, Fisher’s
exact test, for the ratio difference from the synaptic gene set). These
comparisons collectively demonstrate that the ASD enrichment in
module #13 cannot be attributed to only the synaptic genes in this
module, but instead is due to a clustering of ASD genes in the
module. Furthermore, the enrichment was also observed when test-
ing ASD genes from different releases of the SFARI curated database
(P ≤ 1e-10, Supplementary Fig S7).
We next analyzed the association of module #13 with ASD
using data from several unbiased genomic studies (Supplementary
Dataset S2). To account for any potential bias in CDS length or
#2
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Figure 1. A modular protein interaction network with modules containing enrichment of autism-associated genes.
Two topological modules (#2 and #13) on human protein interaction network showed significant enrichment for autism genes (in red). The topological modules are
physical clusters on the network where their member genes intensively interact with each other but sparsely interact with non-member genes on the network. A zoom-in
view of module #13 is also shown, where known autism genes and genes affected by ASD-associated de novo CNVs were colorized in red and green, respectively. Genes
annotated by both were in blue. The false discovery rate indicates its significant enrichment for the known autism genes.
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GC content, all comparisons were based on a set of 9,782 genes
with comparable CDS length and GC content with genes in module
#13 (P = 0.25 and 0.14, respectively, Wilcoxon rank-sum test, see
Materials and Methods). We performed five independent tests
using (i) all the genes whose exons were affected by de novo CNV
events from three independent studies (Levy et al, 2011; Sanders
et al, 2011; Pinto et al, 2014); (ii) a list of 203 high-confidence
genes affected by ASD-associated de novo CNVs detected in 181
individuals with autism (Noh et al, 2013); (iii) 407 genes affected
by rare CNV events associated with ASD (Pinto et al, 2010); (iv)
67 genes affected by de novo loss-of-function mutations in ASD
probands; (v) 366 genes affected by de novo missense mutations
in ASD probands. As control gene sets for these analyses we also
included the following: (vi) 557 genes whose exons were affected
by de novo CNVs identified from non-ASD individuals (Kirov et al,
2012) or unaffected siblings (Levy et al, 2011; Sanders et al,
2011); (vii) 109 genes with de novo missense mutations identified
in unaffected siblings; and (viii) 148 and 52 genes with de novo
silent mutations in ASD probands and unaffected siblings, respec-
tively. All of the above de novo point mutations were from recent
large-scale exome-sequencing studies (Neale et al, 2012; O’Roak
et al, 2012; Sanders et al, 2012). The exact comparisons are
shown in Supplementary Table S1A and B.
We observed that genes affected in ASD patients by the de novo
CNVs (19.33% in the module versus 11.27% in the matched control
gene set, P = 0.01, Fisher’s exact test), the rare CNVs (5.04% in the
module versus 2.17% in the matched control gene set, P = 0.048,
Fisher’s exact test) and the disruptive mutations (2.52% in the
module versus 0.54% in the in the matched control gene set,
P = 0.03, Fisher’s exact test) each displayed a significant enrichment
for this module, whereas the enrichment signal was absent from all
types of mutations identified from non-ASD individuals and unaf-
fected siblings, nor the silent mutations from ASD probands
(P > 0.1, Fisher’s exact test, See Supplementary Table S1A and B for
the exact comparisons). Notably, although all ASD cohorts were
enriched, the strongest enrichment signal was from the high-confi-
dence CNV genes in ASD patients (Noh et al, 2013), where 14.29%
of these genes were implicated in this module compared with 1.1%
in the matched background (P = 3.1e-13, Fisher’s exact test). Lastly,
the similar enrichment was also observed from a set of ASD-
associated genes with syndromic mutations, or highly replicable
genes in different GWAS patient cohorts (P = 3.85e-6, Fisher’s exact
test, scored by SFARI Gene Module, category “S”). Overall, both
curated data and data from genome-wide screening consistently
support a significant association of module #13 with ASD. Our own
sequencing as described in the section below provides further
evidence for this module’s involvement in ASD.
Module #13 was also more enriched for ASD genes (21% in the
module) than genes involved in schizophrenia (Jia et al, 2010)
(10% in the module) and intellectual disability (Parikshak et al,
2013) (9.2% in the module), whereas no enrichment was observed
for Alzheimer’s disease (Bertram et al, 2007) (P = 0.28, Fisher’s
exact test, see Materials and Methods). The increased overlap with
schizophrenia and intellectual disability relative to Alzheimer’s
disease was expected given the shared molecular etiology among
the psychiatric disorders (Lee et al, 2013). Overall, this compari-
son suggests that the module is likely more specific toward
ASD-related genes.
DNA sequencing of ASD patients reveals an enrichment of rare
non-synonymous mutations in this module
We sequenced postmortem brain DNAs collected from 25 ASD
patients (all Europeans, Supplementary Table S2); in 19 subjects,
we sequenced the whole exomes (WES, >97× coverage) and in
six the whole genomes (WGS, ~35–40× coverage). In addition,
we sequenced four genomes and one exome from non-autistic
European individuals to control for the overall sequencing quality
(see Supplementary Tables S2, S3 and S4). We first analyzed
variants identified from the WES platform (19 exomes) and iden-
tified 153 non-synonymous variants that were mapped onto the
module, among which 19.6% (30/153) were extremely rare and
were not previously observed in the 1,000 Genome dataset.
Randomly sampling the same number of genes 10,000 times,
with indistinguishable CDS length and GC content from those in
this module, demonstrated a significant enrichment for the rare
non-synonymous variants in this module (P = 1.2e-3, with the
expected fraction 12%). The same enrichment signal was also
observed from the variants identified by WGS (P = 2.5e-3,
permutation test).
Excluding the variants also identified in the control subjects
that were sequenced on the same platform, we considered 113
non-synonymous sites in this module collectively identified from
WGS or WES. We compared their allele frequencies to those in
the 1,000 Genomes dataset, both the entire global populations and
the European populations, and from the 25 patients, we identified
a total of 38 genes affected by significant non-synonymous vari-
ants in this module with an expected false-positive rate at 0.1
(determined by Fisher’s exact test followed by Benjamini–
Hochberg correction). The high gene overlap between WGS and
WES was not expected by chance (P = 0.03 by random permutation
test). Furthermore, the identification of genes in our module was
not affected by the CDS length of the identified genes relative to
the average CDS length in the module (P = 0.16, Wilcoxon rank-
sum test). The identified genes and a summary of the variant
information are shown in Fig 2A. For example, LRP2 harbored
seven distinct non-synonymous mutations (z-axis, Fig 2A), four of
which were predicted to be deleterious by MutationTaster
(Schwarz et al, 2010). LRP2 has recently been identified as an
ASD candidate gene (Ionita-Laza et al, 2012), whose clinical
mutations cause the Donnai–Barrow syndrome (Kantarci et al,
2007) with the underdeveloped or absent corpus callosum. This
syndrome exhibits many autistic-like symptoms. Figure 2A further
underlines its tissue specificity in the corpus callosum using Brain
Explorer (http://www.brain-map.org). Other well-characterized
ASD-associated genes included SHANK2, SCN1A, NLGN4X and
NLGN3 as well as several LRP2 interacting proteins (LRP2BP,
ANKS1B). Overall, the affected loci in these genes were
more likely to be both rare in the population (y-axis) and
evolutionarily conserved (x-axis), suggesting their functional
importance (Fig 2A). We also noted that 28 genes of the 38 ASD
candidates have not been described previously (see Supplementary
Dataset S3). To better support their association with this
disease, we further examined their mouse mutant phenotypes in
Mouse Genome Informatics (http://www.informatics.jax.org) and
observed that 10 of the 28 new candidate genes displayed
abnormal behavioral traits or a defective nervous system in their
Molecular Systems Biology 10: 774 | 2014 ª 2014 The Authors
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respective mouse mutants (see Supplementary Dataset S3). For
example, mouse mutants of (i) ANKS1B and KCNJ12 exhibited
hyperactivity, (ii) ERBB2IP hyporesponsive behavior to stimuli,
(iii) GRID2IP abnormal reflex and (iv) SCN5A seizure.
Validation using an independent patient cohort
We next sought to further validate our observations in a larger
patient cohort. An exome-sequencing dataset of 505 ASD cases and
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Figure 2. Candidate genes from sequencing screens.
A An overview of the identified loci from whole-genome and exome sequencing. Evolutionary conservation is quantified by GERP++ score, where the higher scores
indicate greater selective pressure on the genomic loci. For genes with multiple significant loci, the most conserved residue is considered. Variants absent in the 1,000
Genome dataset are considered rare variants. The genes were colorized based on the fraction of deleterious mutations predicted by MutationTaster among all the
identified mutations in the gene (MRI image of the corpus callosum: Allen Institute of Brain Science).
B Validation using another larger patient cohort. In this dataset, variants with allele frequencies with increased absolute differences between cases and controls are
more likely to affect genes that were also detected in our study (red line). The allele frequency difference is the absolute difference between cases and controls. This
trend cannot be observed by 10,000 simulations (blue line for one randomized dataset).
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491 controls, each of European ancestry and unrelated within the
cohort, was analyzed (Liu et al, 2013). These samples had been
sequenced using a separate sequencing platform (SOLiD), and the
patients did not overlap with our sequenced cohort (See Materials
and Methods). A previous study examined this dataset but did not
find any genes (or variants) significantly associated with ASD (Liu
et al, 2013). We compared the allele frequencies for each of non-
synonymous variant detected in this study and found ~95% of these
variants had case–control frequency differences below 0.8%. We
observed that genes with non-synonymous variants with the highest
allele frequency differences between cases and controls were more
likely to be in the 38 module-specific candidate genes that we identi-
fied in our sequencing cohort (Fig 2B), and this trend was not
observed when we randomly sampled the same number of genes
from the module for 10,000 times (P = 9.5e-3, Fig 2B). Furthermore,
regression analysis on this dataset identified 16 genes in this module
with the extreme imbalanced allele frequencies among the patient
population (P < 0.05, see Materials and Methods); 14 were in the 38
candidate genes we identified (P = 1.2e-6, hypergeometric test,
Supplementary Dataset S3). Thus, this large-scale exome-sequencing
data validated and extended our results.
Expression specificity of the module in the corpus callosum
We next examined expression of the genes in module #13 using the
Allen Human Brain Atlas (Hawrylycz et al, 2012), which describes
the spatial gene expression across hundreds of neuroanatomically
precise subdivisions as measured by microarray analyses of two
individuals. Since the individuals exhibited high concordance in
expression profiles across brain sections (Hawrylycz et al, 2012),
we averaged the gene expression data for each of the 295 anatomi-
cal brain sections.
Most genes in module #13 were expressed across all brain
sections (Supplementary Fig S8). However, hierarchical clustering
of the normalized gene expression across brain sections revealed
two distinct spatial patterns with some heterogeneity apparent in
each (Fig 3A, complete list in Supplementary Dataset S4). Group 1
had 56 of 119 total genes preferentially expressed in 175 regions (T1
regions in Fig 3A), whereas the 63 genes of Group 2 had elevated
expression in the other 120 brain regions (T2 regions in Fig 3A).
Group 1 genes were strongly expressed in sections associated with
the corpus callosum (Fig 3A, including LRP2 shown in Fig 2A),
which transfers motor, sensory and cognitive signals between the
brain hemispheres. Group 2 genes (e.g., SHANK2 and SHANK3)
were up-regulated in T2 regions, which encompassed neuron-rich
regions, exemplified by the hippocampal formation, including
CA 1/2/3/4 fields, subiculum and dentate gyrus. Tissue enrichment
was derived from relative expression of individual genes across brain
sections; closer examination of their absolute expression in each
brain section relative to the transcriptome background revealed that
Group 1 expression levels were at background levels across most
tissue types, but peaked in the corpus callosum (Supplementary Fig
S8). Group 2 genes were highly expressed across all tissues, albeit
their expression levels were slightly depressed in the corpus callo-
sum (Supplementary Fig S8). Thus, Group 2 genes were more ubiq-
uitously expressed, and Group 1 genes were tissue specific in the
corpus callosum, and the trend was evidenced by its increased
tissue specificity index (P = 1.5e-4, Wilcoxon rank-sum test) and
decreased expression breadth (P < 0.01, Wilcoxon rank-sum test,
Supplementary Fig S9).
We further tested the tissue specificity of expression patterns by
RNA-sequencing (RNA-Seq) of postmortem human brain samples in
two sets of experiments. First, we examined expression levels in
four brain regions of one individual with no known disease (see
Materials and Methods). These regions were the dorsolateral
prefrontal cortex (Brodmann Area 9, BA9), the parietal lobe
(Brodmann Area 40, BA40), the amygdala (AMY) and the corpus
callosum (CC). BA9, BA40 and AMY are neuron-rich regions, while
the corpus callosum is glial rich. Consistent with the microarray
results, Group 2 genes were highly expressed in all tissues (P < 8e-7,
Wilcoxon rank-sum test, Fig 3B) confirming their ubiquitous expres-
sion, and Group 1 genes showed the greatest up-regulation over the
average transcriptome background in the corpus callosum
(P < 1.6e-6, Wilcoxon rank-sum test, Fig 3B) confirming their
increased tissue specificity. These RNA-Seq experiments also
confirmed the tissue specificity of LRP2 in the corpus callosum
(Supplementary Fig S10), as expected from Fig 2A. Secondly, to rule
out individual variability, we also examined gene expression by
RNA-Seq of the corpus callosum from six normal individuals (all
young Caucasian males; the control subjects in our later RNA-Seq
experiments, Materials and Methods). We found that both Group 1
and 2 genes were highly expressed in the corpus callosum relative
to the transcriptome background (P < 4.87e-6, Wilcoxon rank-sum
test, Fig 3C). These results confirmed that module #13 as a whole is
highly expressed in the corpus callosum, the largest white matter
structure in human brain.
To further validate our results, we performed immunohistochem-
ical analyses for a Group 1 corpus callosum-specific gene (Supple-
mentary Fig S10), LRP2, that also showed excessive mutation in our
sequencing analyses (Fig 2A). The experiment was performed in the
frozen postmortem corpus callosum tissue from one autism patient
(Fig 4A) and one control subject (Supplementary Fig S11). LRP2
protein was significantly expressed in the corpus callosum in both
individuals, with no obvious difference between the normal and
ASD subjects. As shown in Fig 4A, the staining results further
revealed that the human corpus callosum was predominantly popu-
lated by oligodendrocyte cells.
Given this fact, we next explored the function of this module in
the oligodendrocytes by comparing gene expression of module #13
with other major cell types (neurons and astrocytes) in brain. Due
to a lack of the cell-type expression data in human brain, we
mapped module #13 onto their unambiguous mouse orthologs (the
one-to-one orthology) and analyzed their cell-type expression
(Cahoy et al, 2008). Hierarchical clustering revealed that the
mouse orthologs in our module formed two major clusters with
expression enrichments in either neurons or glial cells (i.e., oligo-
dendrocytes and astrocytes, Fig 4B). The expression profiles of
glial cells were significantly enriched for Group 1 genes, and of
neuronal cells for Group 2 genes (P = 6.4e-4, chi-square test,
Fig 4B), suggesting that expression propensities of Group 1 and 2
in sections T1 and T2 (Fig 3A), respectively, were largely due to
their different compositions of glial cells and neurons. However, a
portion of the genes in both the neuron and glial clusters showed
common enrichment in the oligodendrocytes, separating the
cluster of the myelinating oligodendrocytes (myelin OLs, the
sub-cluster on the x-axis, Fig 4B) from the non-myelinating
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oligodendrocytes (the newly differentiated oligodendrocytes, OLs
and the oligodendrocyte precursor cells, OPCs, the sub-cluster on
the x-axis, Fig 4B). We thus hypothesized that the two sub-
components (Group 1 and 2) in the module are likely to be
involved in the development of oligodendrocyte cells.
Using the data generated by Emery et al (2009), we next
compared gene expression of the mouse orthologs of Group 1 and 2
genes in differentiating mouse culture systems. In cultured oligoden-
drocyte precursor cells (OPCs), the two gene groups did not show
substantial expression changes relative to the transcriptome average
(Fig 4C). However, in the matured myelinating oligodendrocytes
(MOG+), Group 1 genes exhibited marked up-regulation (P = 3.0e-3,
Wilcoxon rank-sum test, Fig 4D), whereas the Group 2 genes showed
slight down-regulation with no statistical significance (P = 0.74,
Wilcoxon rank-sum test). This indicates that up-regulation of Group
1 genes is associated with oligodendrocyte maturation.
In the same mature oligodendrocytes, we tested the expression
of module #13 components using mouse knockouts (Emery et al,
2009). The transcription factor, myelin gene regulatory factor
(MRF), plays a central role in developing myelination capacity for
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oligodendrocyte cells, and mice lacking MRF in the oligodendro-
cyte lineage show defects of myelination, accompanied by severe
neurological abnormalities and postnatal lethality due to seizures
(Emery et al, 2009). In mouse oligodendrocytes with a conditional
knockout of MRF (MRFfl/fl; Olig2wt/cre), Group 2 genes exhibited a
significant up-regulation relative to the transcriptome background
(P = 8.7e-4, Wilcoxon rank-sum test, Fig 4D), whereas Group 1
genes underwent down-regulation with marginal statistical signifi-
cance (P = 0.1, Wilcoxon rank-sum test, Fig 4D). This suggests
that Group 2 genes are directly or indirectly suppressed by the
master myelination factor MRF in the myelinating oligodendro-
cytes. Overall, given these observations, we propose that up-
regulation of the Group 1 genes in this module is associated with,
or likely contributes to, oligodendrocyte maturation from their
precursor cells (OPSc). However, in the mature oligodendrocytes,
myelination capacity is acquired by the MRF-mediated regulatory
network, which also serves to suppress expression of the Group 2
genes (Fig 4E).
Altered gene expression in the corpus callosum of ASD patients
revealed by RNA-sequencing
Given the apparent importance of oligodendrocytes in the corpus
callosum, we further hypothesized that gene expression in this
module is likely to be perturbed in the corpus callosum of ASD
patients. We obtained frozen postmortem samples from six young
Caucasian males with a diagnosis of autism together with their
respective matched controls from the NICHD Brain and Tissue
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A Immunohistochemistry analysis in the corpus callosum. Staining of LRP2 in the human corpus callosum reveals that the major cell population in the corpus callosum
is the oligodendrocytes (the blue round nuclei), which express LRP2 stained in brown. A zoom-in view is shown in the inset.
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C Overall expression of module #13 in cultured oligodendrocyte precursor cells (OPCs). Group 1 and 2 were expressed at a similar level as the transcriptome
background in OPCs. The statistical significance was determined by Wilcoxon rank-sum test, and the error bars represent one standard error.
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E A proposed model. Up-regulation is associated with, or likely to contribute to, the differentiation of OPCs into mature myelinating OLs. The mature OLs acquire their
myelination capacity by activating the MRF-mediated regulatory network, which also serves to repress expression of Group 2 genes.
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Bank (Materials and Methods and Supplementary Table S5). Total
RNAs were prepared and subjected to high-coverage (180M reads/
sample) deep RNA-sequencing. Biological replicates (with the
same sequencing depth) were performed on half of the samples,
using different sections of the same tissue block. The biological
replicates produced highly reproducible results with a median
Pearson’s coefficient equal to 0.95 (range 0.9–0.96; Supplementary
Fig S12), whereas the correlations among samples from different
individuals were substantially lower (median correlation coeffi-
cient 0.89, P = 4.4e-3, Wilcoxon rank-sum test), demonstrating the
high intra-individual reproducibility of our platform. Because gene
expression in the brain is age dependent in patients with autism
(Chow et al, 2012), we compared gene expression in each case–
control pair with identical age, ethnicity, sex and comparable post-
mortem intervals (PMIs). We then identified genes showing the
most extreme expression changes in at least one case–control pair
(fold change > 2, above the 97.5% upper bound for up-regulation
and below 2.5% for down-regulation across the entire transcripto-
mes, Supplementary Table S6). Genes encoding components of the
module #13 showed significant enrichment for the differentially
expressed genes relative to the genes encoding the entire protein
interaction network (P = 5e-4, hypergeometric test, Fig 5A). We
conducted comparisons against two control gene sets: a complete
list of 1,886 known synapse-related genes (the synaptome in
Fig 5A) from SynaptomeDB (Pirooznia et al, 2012) and the other
control included a list of known 383 autism candidate genes repre-
sented on the network. In each case, the gene set contained a
similar fraction of differentially expressed genes as the entire tran-
scriptome background (P = 0.39 and 0.14, hypergeometric tests,
respectively). Thus, expression of module #13, but not synaptic
genes in general or known ASD candidate genes, was significantly
altered in the corpus callosum of the ASD patients relative to the
matched controls.
A network view of the candidate loci in this ASD module
We postulated that genes associated with ASD might show common
patterns in their topological positions on the molecular network,
and thus, we used the protein interaction network to integrate our
findings from the genome sequencing and expression analyses for
the module. The global interactome can be viewed as a layered
structure with proteins distributed from central cores to peripheral
layers. This can be revealed by the k-core decomposition algorithm
(Materials and Methods, also see the layered structure in Supple-
mentary Fig S13), where the coreness K of a protein describes its
closeness toward the network center. Proteins with K = 1 are
peripheral nodes that are individually connected, and proteins with
K ≥ 10 lie in the center of the network (the entire K distribution is
shown in Supplementary Fig S14). A previous study has shown that
the proportion of essential and conserved proteins increased succes-
sively toward the network’s innermost cores (Wuchty & Almaas,
2005).
By combining the 38 genes with at least one significant non-
synonymous variant detected from our whole-genome and exome
sequencing (Fig 2A), we examined the fraction of genes with the
significant variants as a function of their coreness K in the module.
As shown in Fig 5B, within this module, a significantly high propor-
tion of central proteins were affected by mutations in individuals
with ASD (P = 4.5e-2, hypergeometric test), whereas a significant
depletion was manifested in the intermediate layer (3 ≤ K < 6)
(P = 0.01, hypergeometric test). The peripheral nodes were also
enriched for mutations in the module, but these were not statisti-
cally significant. By randomly sampling the same number of genes
from the module 10,000 times, we found that the particular U-shape
distribution was not expected by chance (P = 4.0e-4), suggesting
that network topology is indeed correlated with gene mutation
frequency in ASD patients.
We also examined brain tissue gene expression as a function of
network coreness K. Analysis of the different layers of the network
revealed that protein products of the genes centered in the network
(K ≥ 10, Fig 5B) were significantly biased toward the corpus callo-
sum-specific sub-component (Group 1; Fig 5C, P = 0.01, hypergeo-
metric test). These observations were also observed using the
independent 500-patient cohort (P ≤ 0.05, hypergeometric test).
Further analysis of the corpus callosum RNA-sequencing data from
the six non-autistic subjects (Supplementary Table S5) revealed a
positive correlation between the network coreness and their expres-
sion levels for individual genes in module #13 (r = 0.32, P = 3.7e-4,
Spearman’s correlation, Fig 5D). These observations collectively
indicate that the central genes may play fundamentally important
roles in the corpus callosum as they are preferentially expressed in
this tissue and pathogenic mutations of ASD patients more likely lie
in these genes. We note that two genes, DYNLL1 and BCAS1,
displayed extreme expression in the corpus callosum (Fig 5D) with
FPKMs > 130. Examination of their expression in the three neuronal
regions (BA9, BA40 and AMY, Fig 3B) revealed that DYNLL1 is a
ubiquitously expressed gene with high expression across all the
brain sections, whereas the extreme expression of BACS1 was
unique only in the corpus callosum (FPKM < 20 in other neuronal
regions). Its specific expression in the corpus callosum was further
confirmed on the microarray data from Allen Brain Atlas, suggesting
a novel function of this gene in the corpus callosum.
Affected sub-complexes in this ASD module
To characterize the module at higher resolution, we decomposed it
into 21 sub-clusters (Fig 5E) using the algorithm in Fig 1. Functional
coherence among genes within the same sub-complexes was
observed; for example, EXOC3–6 were clustered in the fourth sub-
complex, consistent with their co-complex membership by recent
mass spectrometry profiling (Havugimana et al, 2012). The second
sub-complex contained glutamate receptors, encompassing AMPA,
kainate and NMDA families, delineating the collaborative nature of
these receptor proteins. Most interestingly, many known genes
implicated in ASD were also co-clustered, such as the co-clustering
of NLGN1-3 with NRXN2-3, suggesting mutations on these genes
are likely to perturb a common protein complex. In general, except
for one sub-complex (THAP10-DYNLL2-DNAL4), all others have
been affected by either mutations or mis-expression of at least one
member protein, suggesting a pervasive role of this module underly-
ing ASD etiology. Notably, the sixth and eighth sub-clusters showed
significant enrichment for both the differentially expressed genes
(P = 0.035, hypergeometric test) and the mutated genes (P = 0.036,
hypergeometric test), respectively (Fig 5E). The sixth sub-cluster
revealed interaction between the DLGAP (DLGAP1-4) and SHANK
proteins, all of which are part of the postsynaptic scaffold. In
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Figure 5. Integrative analysis of the genetic alteration in this study.
A Enrichment of the differentially expressed genes in module #13. RNA-sequencing of the corpus callosum of autism patients and their matched controls. Enrichment
was not observed for the genes in the human synaptome or the collection of known autism genes (excluding genes in this module). Statistical significance was
determined by hypergeometric test.
B The mutation pattern of the genes from the innermost layers of the interaction network (K ≥ 10) to the periphery layer (K = 1). Genes in the central and periphery
layers in this module are more likely to be affected, while the trend cannot be observed in 10,000 random simulations. For individual bins, significant enrichment and
depletion were observed in the central layers (K ≥ 10) and the intermediate layers (3 ≤ K < 6), respectively. Statistical significance of the enrichment was determined
by hypergeometric test. 10,000 random permutations were performed to determine the statistical significance of the curve.
C Compositional bias of the mutated genes in central layers. The mutated genes in central layers are more biased toward the corpus callosum-specific subcomponent;
this trend is not observed in background or other mutated genes with varying degree of K. Statistical significance of the enrichment was determined by
hypergeometric test.
D Positive correlation between network coreness and gene expression in the corpus callosum. RNA-sequencing of the corpus callosum of six non-autistic individuals
revealed a positive correlation, suggesting the central layers may play critical roles in the corpus callosum. Two outlier genes, DYNLL1 and BCAS1, are separately
labeled due to their extreme expression in this tissue. The correlation coefficient r and its statistical significance were computed using Spearman’s correlation.
E Predicted sub-complexes within this module. Genes in this module are topologically clustered to form sub-complexes, with the significantly mutated genes
labeled in blue, mis-expressed genes in the corpus callosum labeled in green, and both in red. Two clusters, #6 for SHANK-DLGAP complexes and #6 for
LRP2, and its binding partners, are enriched for the mis-expressed or mutated genes, respectively. Statistical significance of the enrichment was determined
by hypergeometric test.
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addition, genes in the eighth sub-complex were preferentially
mutated in our screen, which characterized another pathway involv-
ing the corpus callosum-specific protein LRP2. Overall, these results
further delineate the substructure of the components and complexes
that comprise the ASD-associated module.
Discussion
Most of our knowledge today about ASD genetics has been gained
from genetic association or exome-sequencing analyses of large ASD
patient cohorts, which allows us to begin to observe the molecular
underpinnings of this disease. However, a complete picture for this
disease may require an integration of ASD genetic data from differ-
ent dimensions. For example, a number of studies have analyzed
genes that displayed differential expression in ASD brains (Voineagu
et al, 2011; Chow et al, 2012), but aberrant mutations have not yet
been identified for many of these genes. Since the retention of
genetic mutations within a population is strongly driven by natural
selection and population demographics (Hartl & Clark, 2007), muta-
tions in genes critical for ASD are likely to be depleted by purifying
selection or simply by population bottleneck, preventing the identifi-
cation of ASD candidate genes only from mutational analyses. In
addition, another example of a gene that would be missed by differ-
ential expression studies is LRP2, whose implication in ASD was
found by this study and also an earlier investigation (Ionita-Laza
et al, 2012), but it did not exhibit altered expression in ASD
patients. These observations strongly suggest that genetic alterations
leading to ASD might occur at different levels, perturbing gene regu-
lation or affecting gene function, and highlight the importance of
building an integrative model to study ASD, where genomic data
from multiple independent dimensions are incorporated to reveal
the hidden architecture of this disease.
The integrative framework presented in this study is such an
example to unravel the natural and physical organization of compo-
nents implicated in ASD. We leveraged abundant genomic data
including the human protein interactome, the transcriptome data in
human and mouse brain, the MRF knockout data in mouse oligo-
dendrocytes and also the mutation data from previous ASD sequenc-
ing projects. In addition, we also independently sequenced the
genomes, exomes and transcriptomes in patients’ brains to validate
our observations from those publically available data or to gain new
insights into this disease. Our integrative approach incorporated
these genomic data of diverse dimensions, suggesting several key
findings relevant to autism. First, we observed the modular struc-
ture of the human protein interactome, where genes forming a natu-
ral topological cluster tend to have shared functions. In particular,
module #2 (with GO enrichment for gene regulation) and #13 (with
GO enrichment for synaptic transmission) showed statistically
significant enrichment for ASD genes. Their enriched functional
categories are consistent with earlier studies for de novo mutations
associated with ASD (O’Roak et al, 2012; Ben-David & Shifman,
2013). These observations suggest convergent functional modules
underlying the seemingly heterogeneous mutations associated with
ASD.
Because of its high enrichment, we specifically studied module
#13, and a second key finding is that this module had dichotomized
spatial expression pattern across human brain: one sub-component
(Group 2 genes) ubiquitously expressed and one with enhanced
molecular expression in the corpus callosum (Group 1 genes). Both
interact extensively with each other. We confirmed using RNA-Seq,
microarrays and immunohistochemical staining that the module as
a whole was expressed in the corpus callosum, a brain structure
predominantly constituted by axons and oligodendrocyte cells. Up-
regulation of Group 1 genes was associated with oligodendrocyte
maturation from OPC cells (Fig 4D). Considering that the expression
of Group 1 genes is highly enriched in the corpus callosum, we spec-
ulate that this sub-component is likely involved in differentiating
OPCs in the corpus callosum. Genes in this group include KCNJ10
(potassium inwardly rectifying channel, subfamily J, member 10),
which exhibited tenfold up-regulation from OPCs to the matured
myelinating oligodendrocytes, suggesting a strong role of this gene
in oligodendrocyte development. Importantly, mutations in this
gene were identified among ASD patients from our exome/genome
sequencing and also in an earlier study from a different patient
cohort (Sicca et al, 2011). Meanwhile, aberrant mutations in this
gene were also found to be associated with seizure susceptibility
(Buono et al, 2004), a condition commonly comorbid with ASD.
These observations support the potential role of oligodendrocytes in
the development of autism. Group 2 genes, in addition to their rela-
tively high expression in the corpus callosum (Fig 3C), showed the
strongest expression in neuronal regions in brain (Figs 3B and 4B),
explaining the high enrichment signal of synaptic genes in module
#13 in our initial GO enrichment analysis. This observation supports
the synaptic theory of this disease.
The corpus callosum plays a central role in mediating signal
communication between the brain hemispheres through the axons
extending from different cortical layers; thus, appropriate myelina-
tion by the oligodendrocytes for the axons is key for the process.
We further observed that conditional knockout of the myelination
regulatory factor (MRF) in the matured oligodendrocyte cells signifi-
cantly up-regulated Group 2 genes, which were otherwise highly
expressed in neuron-rich regions. Collectively given the functions of
module #13 involved in the development of oligodendrocytes, the
major cell type in the corpus callosum, our study likely provides a
molecular clue to the reduced size of the corpus callosum that has
been observed among individuals with ASD (Egaas et al, 1995).
Two recent studies (Parikshak et al, 2013; Willsey et al, 2013)
have implicated the superficial cortical layer (II/III) or the deep
cortical regions (layer V/VI) in ASD. Callosal projection neurons are
primarily localized in the superficial layers II/III (~80%) or deep
layers V/VI (~20%); thus, our study now connected the two studies
suggesting a critical role of the interhemispheric connectivity
circuitry, whereby disrupting its sub-components to affect the inter-
hemispheric signal transduction through the corpus callosum will
likely to give rise to ASD phenotypes. Therefore, the disease etiology
should be understood at the level of the complete interhemispheric
connectivity circuitry, not simply by a particular brain region or cell
type. This could not only explain the enrichment in ASD-associated
mutations in genes highly expressed in the constitutive parts of the
circuitry (superficial or deep cortical layers in the earlier studies, or
in the corpus callosum in this study), but also might provide a
molecular basis for the observation from the imaging studies of the
under-development of the corpus callosum among ASD patients.
Importantly, different from previous research, our study illustrates
the role of the oligodendrocyte cells in ASD, which myelinate and
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support the axons in the corpus callosum for interhemispheric
signal transduction. Since current ASD research has been primarily
focused on neuronal regions, future study is warranted to examine
the implications of other cell types in this disease.
Two groups of genes were identified previously which displayed
elevated expression in the corpus callosum, but were not signifi-
cantly associated with ASD (Ben-David & Shifman, 2012). The
overlap between our module and these genes was restricted to two
genes. Meanwhile, only four of our genes overlapped with those
from NETBAG (Gilman et al, 2011), which identified the function-
ally associated genes affected by rare de novo CNVs in autism. Nota-
bly, a more recent paper considered a sub-network implicated in
ASD constituted by known ASD candidate genes and their first-
degree interacting neighbors (An et al, 2014; Cristino et al, 2014).
This empirical network was large and encompassed more than
2,000 genes for ASD, but ~30% of genes in our module were not
captured by their empirical network. Worthy of note, based on inde-
pendent yeast-two-hybrid screens, recent studies have attempted to
generate the complete interactomes for individual proteins impli-
cated in ASD (Sakai et al, 2011; Corominas et al, 2014), and thus,
we envision a significant expansion of our current observation when
the human protein interactome is more complete.
In conclusion, by using an integrative framework, we were able
to examine the convergence of clinical mutations onto specific
disease-related pathways. The framework provided in this work
might be used to uncover functional modules for other diseases,
improving their risk assessment.
Materials and Methods
Network compilation and operations
The human protein interaction network used in this study was
downloaded from BioGrid database (rel.3.1.92) (Stark et al, 2011),
where high-quality protein interactions were collected by the cura-
tion team. We removed the isolated nodes, self-interacting edges
and interactions between human and non-human proteins from the
network. We analyzed a total of 13,039 proteins and 69,113 interac-
tions. To first assess the quality of this network, we examined gene
co-expression between the reported interacting proteins, which has
been used previously to examine the quality of protein interactions
(Yu et al, 2008). We compared gene co-expression between the
BioGrid interactome with a set of benchmarked high-confidence
human interacting proteins (HINT) (Das & Yu, 2012; Wang et al,
2012) and also with a set of randomly paired proteins. The expres-
sion dataset encompassing 79 human tissues and cell types (Su
et al, 2002) was used for the co-expression analysis, where probe
identifies from the microarray platform were mapped onto their
Entrez identifiers, and signals of multiple probes corresponding to a
single Entrez gene were averaged. Pearson’s pairwise correlation
was then computed for protein pairs in each dataset.
Having assessed the overall quality of the network, we next topo-
logically decomposed the global protein interaction network into a
set of network modules with dense interactions within a module
and sparse interactions between modules. The network decomposi-
tion algorithm was first described in a previous publication, which
showed significant improvement compared with other methods
(Blondel et al, 2008). The modules in this study were from the first-
pass partitioning of the network without further grouping small
modules into larger ones. This practice gave more specific insights
into module functions. The power-law distribution of the module
sizes (Supplementary Fig S3A) was based on a statistic test for
empirical data (Clauset et al, 2009). To test whether the modularity
of the network can be observed by chance, we generated 100
randomized networks by shuffling edges of each node but main-
tained its degree (degree-preserving shuffling (Milo et al, 2002))
(Supplementary Fig S3B). We also performed Markov clustering
algorithm (MCL) and affinity propagation (Vlasblom & Wodak,
2009) to divide the network, but their performance was not satisfac-
tory, where the resulting network modularity scores Q were signifi-
cantly lower than that of the algorithm used in this study. These
network operations were based on FUGA (Drozdov et al, 2011).
Network visualization was implemented by CytoScape v2.8.3
(http://www.cytoscape.org). The layered structure of the protein
interaction network was decomposed with the k-core algorithm
implemented by MatlabBGL (http://dgleich.github.io/matlab-bgl/).
Visualization of the layered structure by k-core decomposition was
implemented by LaNet-vi (http://lanet-vi.soic.indiana.edu).
We examined GO enrichment for each of the decomposed
network module to infer their biological relevance. GO annotations
(excluding IEA terms) were downloaded from http://www.geneon-
tology.org (as of Sep. 2012). The hypergeometric test was performed
to determine GO enrichment, followed by FDR correction (false
discovery rate). In each of the tests, we only considered modules
with more than five genes. To justify this size threshold selection,
we varied the threshold from 1 to 20 genes and identified n = 5 was
the optimal threshold, which has balanced sensitivity and specificity
(Supplementary Fig S4B). Specifically, in Supplementary Fig S4B,
the blue curve (with red circles) showed the number of clusters with
GO enrichment above a given size threshold, and the black curve
(with green squares) was the gradients of the blue curve at each
threshold, which detected the pattern changes on the blue curve. It
is clear that the number of GO-enriched clusters decreased rapidly
with the increase of the threshold when the threshold was < 5 (from
~200 clusters at threshold n = 1 down to 85 at the threshold n = 5,
the blue curve). This threshold-sensitive pattern was recapitulated
by the rapid increase in the gradients at each threshold points, espe-
cially by the two consecutive rises in the gradients from threshold
n = 3 to n = 4 and from n = 4 to n = 5 (black curve), transitioning
from a threshold-sensitive regime into a threshold-insensitive
regime. After the threshold n = 5, the blue curve gradually
decreased and reached convergence after n = 8, accompanied with
the almost flat gradient curve (the black curve), which, however,
suggests the threshold n ≥ 8 would be too conservative. Thus, in
this study, we used the turning point n = 5 as our threshold to
trade-off specificity and sensitivity. Furthermore, for module #13,
we also considered the sources of the curated interactions. Module
#13 consists of 119 proteins mediating 275 interactions and was
derived from 109 different publications (with different PubMed IDs,
on average ~2.5 interactions per publication), compared with a total
of 16,140 PubMed IDs for 69,113 interactions in the whole network
(on average ~4.28 interactions per publication). The elevated diver-
sity of experimental sources for this module suggests that its
network modularity was less likely to be biased toward a particular
experimental platform.
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The enrichment of module #13 for ASD gene candidates curated
from SFARI
To determine the associations of the network modules with ASD,
we first considered the curated genes implicated in ASD and then
generalized our comparisons to genes from unbiased genome-wide
screens. We first retrieved known autism-associated genes from
SFARI Gene (https://gene.sfari.org/ autdb/). Among a total of 484
genes in the database (as of February, 2013), 383 were on the
protein interaction network. Different versions of these annotated
genes were also considered. In addition to using the hypergeometric
test to assess the enrichment of the SFARI genes in module #13, we
perform a set of permutation tests to ensure that the comparison
was not biased by unequal CDS length or GC content. Briefly, we
compiled a list of 10,390 genes whose CDS length (the longest
RefSeq transcript, Ensembl 72) was similar with the SFARI genes
(P = 0.24, Wilcoxon rank-sum test). Furthermore, we also compiled
a list of 14,041 genes, whose GC content in CDS was similar with
the SFARI genes (P = 0.58, Wilcoxon rank-sum test). We then
considered the intersection between the two gene sets, totaling
7,743 genes (excluding the SFARI genes). Among this gene set with
indistinguishable CDS length and GC content, we randomly sampled
383 genes, the same number with the SFARI genes, for 10,000 times
(the pseudo-ASD risk genes), and we found that none of the 10,000
random simulations overlapped with module #13 more than the real
SFARI gene list, giving an empirical P < 1e-5. We also used genes
annotated by SynaptomeDB (Pirooznia et al, 2012) to control for
potential bias from known synaptic genes in this comparison.
The enrichment of module #13 for ASD gene candidates from
genome-wide screens
To determine the enrichment in module #13 for genes implicated in
ASD from genome-wide screens, we compared genes in module #13
with 9,782 background genes with indistinguishable CDS length and
GC content (P > 0.05, Wilcoxon rank-sum test, as described above),
and this set of control genes was not overlapping with module #13.
For each set of ASD candidate genes (identified by CNV, exome-
sequencing studies, etc., Supplementary Table S1), we asked
whether or not the module was more enriched for these ASD candi-
date genes than the matched control gene sets. The exact compari-
sons can be found in Supplementary Table S1B, where we
considered ASD candidate genes affected by de novo CNVs, rare
CNVs, de novo disruptive, missense and silent mutations from large
collection of ASD probands. The same categories of mutations iden-
tified from non-ASD individuals or the matched unaffected siblings
were also analyzed in Supplementary Table S1B. The references for
the data sources can be found in Supplementary Table S1A and B,
and the complete gene list can be found in Supplementary Dataset
S2. Particularly for the de novo CNV datasets, we first considered de
novo CNVs (annotated as “de novo” in their final category) identi-
fied from ASD probands from a recent publication (Pinto et al,
2014). In addition, de novo CNVs from two early studies were also
considered (Levy et al, 2011; Sanders et al, 2011). The union and
the intersection of the de novo CNV datasets from Pinto et al and
those from Sanders et al or from Levy et al were separately tested.
Genes with at least one exon affected by these de novo CNVs were
considered for both ASD and non-ASD subjects. The de novo CNVs
for non-ASD subjects were collected from a recent publication
(Kirov et al, 2012). This control CNV dataset was combined with
those identified from the unaffected siblings in Sanders et al and
Levy et al. Since these de novo CNVs affected thousands of genes in
the genome, we also considered a small set of strong candidate
genes affected by the ASD-associated high-confidence de novo CNVs
in this comparison, and these genes were identified from a previous
study (Noh et al, 2013).
Collection of genes involved in other psychiatric diseases
We additionally tested enrichment signals in module #13 for genes
implicated in schizophrenia, intellectual disability and Alzheimer’s
diseases. Genes in schizophrenia were obtained from SZGR (http://
bioinfo.mc.vanderbilt.edu/SZGR/index.jsp), where 38 core genes
and 278 protein-coding genes representing confident loci from previ-
ous genome-wide association studies were considered. 613 genes
implicated Alzheimer’s disease were obtained from AlzGene
(http://www.alzgene.org). Genes implicated in intellectual disabil-
ity were collected in a recent publication (Parikshak et al, 2013).
Whole-genome and exome-sequencing protocols
Sample information
Samples were requested from two sources, Autism Speak’s Autism
Tissue Program (ATP) and NICHD Brain and Tissue Bank (NICHD).
Sample information can be found in Supplementary Table S2.
Autism diagnosis was confirmed by the clinical practitioners in the
brain banks with ADI-R (Autism Diagnosis Interview–Revised). The
ATP samples covered the most case DNAs in the ATP’s repository
(excluding 15q duplication, epilepsy, Angelman syndrome samples
or samples from patients’ siblings or samples with no sufficient
DNA amount).
Sequencing protocol
The genomic DNAs from ATP were extracted from the occipital
lobe, Broadmann Area (BA19). We received frozen tissue blocks
(postmortem corpus callosum) of six patients from NICHD and
extracted genomic DNAs with the use of QIAGEN’s DNeasy Blood &
Tissue Kit. We used 5 lg DNAs for genome sequencing and 3 lg
DNAs for exome sequencing. DNA quality was examined on agarose
gel electrophoresis prior to library preparation. Sequencing was on
Illumina’s HiSeq 2000 platform with 101 × 2 pair-end adaptors.
WGS samples were subject to standard Illumina’s procedures with
variants called by the company’s software CASAVA. The called vari-
ants were further validated with the Illumina Omni genotyping SNP
array with overall concordance rates of ~99.28%.
The variants were further filtered by removing variants falling in
the segmental duplication, simple repeat regions, etc. For exome
sequencing, GATK (ver. 2.3.9) was used to call variants by aggregat-
ing samples over the targeted intervals designed for exome capture,
reaching the average ratio of Ti/Tv 3.18. Agilent SureSelectXT kit
(Human All Exon V5+UTRs) was used for exome pull-down in this
study. Coverage and Ti/Tv values (transition to transversion rates)
for individual samples in WGS and exome sequencing can be
found in Supplementary Tables S3 and S4. Variants were annotated
using ANNOVAR (Wang et al, 2010) based on human genome build
hg19.
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Analysis
Fisher’s exact test was used to identify alleles overrepresented in the
patient cohort. 1,000 Genome variants’ allele frequencies in all
samples or only in Europeans were referenced in the analysis. The
P-values for variants in this module were further corrected with the
Benjamini–Hochberg procedure. The functional consequences of the
identified variants were tested by MutationTaster (Schwarz et al,
2010), where the automatic annotations based on the 1,000 Genome
frequencies were overridden by the prediction from the original
Bayesian classifier. Phenotypic analysis of the identified genes was
based on the component of Human-Mouse: Disease Connection
in Mouse Genome Informatics (http://www.informatics.jax.org/
humanDisease.shtml).
Validation using dbGAP data
We were approved to use one exome-sequencing dataset in dbGAP,
which sequenced a larger patient population in previous study (Liu
et al, 2013). Half of the samples were sequenced in Broad Institute
(by the Illumina platform) and the other half in Baylor College Medi-
cine (BCM, by the SOLiD platform). Due to incomplete data depos-
ited in dbGAP for those sequenced on the Illumina platform, we
were only able to study the subjects sequenced by BCM, including
505 unrelated patients and 491 controls, all with European ethnicity.
Variants showing the most significant deviation in their allele
frequencies from the control subjects were identified with a regres-
sion analysis. We regressed case/control frequencies reciprocally,
followed by a residue analysis that identified outliers exceeding
the upper 5% bound of the residue distribution modeled by a
t-distribution.
Expression analyses of the module across brain sections
Expression data were from Allen Brain Atlas (Hawrylycz et al,
2012), where gene expression was measured with microarrays
across hundreds of anatomical sections in two representative indi-
viduals (9,861 and 10,021). The microarray data had been normal-
ized and postprocessed by Allele Brain Atlas, and we considered
295 brain sections that were measured in both individuals (by
matching the brain section identifiers). Expression of a given gene
in a given tissue was then averaged over the two individuals to
reduce the potential individual-specific fluctuations. In addition,
signals of multiple probes mapped onto the same transcripts were
also averaged in this analysis. The expression profiles were then
normalized across sections followed by a hierarchical clustering,
which allowed identifying gene groups sharing similar spatial
expression patterns. In each brain section, the absolute expression
of genes in Group 1 and 2 was also compared against the tran-
scriptomic background in the corresponding section. Tissue speci-
ficity index was computed for individual genes across the 295
brain sections using the following formula defined in a previous
study (Yanai et al, 2005), s ¼PNi¼1 ð1 xiÞ=N  1, where s is the
tissue specificity index of a given gene, N is the total number of
different brain sections, and xi is the gene’s expression in a
section, i. Expression breadth of a given gene was determined by
the number of brain sections where the gene is active, and we
varied the threshold to define gene activity based on the distribu-
tion of the absolute gene expression across the transcriptomes in
the 295 brain sections (Supplementary Fig S9). The thresholds
chosen in our comparison were 15, 25 and 50% of the data points
across all genes, and expression values below these cutoffs were
deemed to be inactive.
Genes in this module were further mapped onto the mouse
genome by identifying their one-to-one mouse orthologs based on
Ensembl Gene (as of August, 2013). Mouse expression data for
neurons, oligodendrocytes and astrocytes were retrieved from a
previous study (Cahoy et al, 2008). Chi-square test was used to
determine the imbalanced distribution of genes in Group 1 and 2 in
the neuron and glial cluster, respectively (Fig 4B). Mouse expres-
sion data in the oligodendrocyte precursor cells (OPCs), the mature
oligodendrocytes (OLs) and the MRF conditional knockouts were
retrieved from a previous study (Emery et al, 2009). We mapped
the probes onto mouse gene symbols and averaged signals from
multiple probes mapped onto the same genes. Expression across
multiple biological replicates under the same condition was
averaged.
Immunohistochemistry analysis of the postmortem
corpus callosum
Immunohistochemistry analysis was performed on the corpus callo-
sum from a patient (#5308) and a control subject (#4727). Anti-
LRP2 antibody was purchased from Abcam (cat#: ab76969, Abcam,
Cambridge, MA). Immunohistochemistry labeling for LRP2 was
carried out using the DAKO EnVision system (cat#: K4065, DAKO,
Carpinteria, CA) at 1:100; slides were developed using the Dako
Envision method as the manual suggested. Heat-induced antigen
retrieval was performed with Decloaking Chamber (Biocare Medical,
Concord, CA) in citrate buffer (pH 6.0). Human kidney carcinoma
tissue and normal human ovary were used as positive and negative
controls given the presence and absence of LRP2 (from literature) in
these two tissues, respectively. In addition, IgG was also used as a
control for the specificity of anti-LRP2. Cell types in the corpus
callosum were independently identified and verified by a neuro-
pathologist at Stanford.
RNA-sequencing protocols
Sample information
Postmortem tissues of corpus callosum from 12 individuals were
subject to RNA-sequencing in this study. Frozen tissue blocks were
all provided by NICHD Brain and Tissue Bank. The samples were all
European males, and case–control pairs were matched in terms of
their age, sex and PMI (depends on tissue availability). All the
control subjects have been optimized for comparisons and were
selected by the brain bank to match the cases. The case–control
pairs are listed in Supplementary Table S5. We also biologically
replicated our experiments on 6 out of 12 individuals by sectioning
different areas of the tissue blocks. In addition to the corpus callo-
sum, we also sequenced three brain sections (NICHD) for a control
subject #5407 (Supplementary Table S5), including Brodmann areas
9, 40, and also the amygdala.
Sequencing protocols
Total RNA was extracted from flash-frozen tissue samples using
Trizol reagent. Then, the total RNA was treated with RNase-Free
DNase (Qiagen) followed by purification with RNeasy MinElute
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Cleanup Kit (Qiagen) following the manufacturer’s instructions.
2 lg of total RNA each sample was subject to RNA-Seq library
preparation with ScriptSeqTM Complete Gold Kit from Epicentre
(Cat. #SCL24EP, Madison, WI) following the manufacturer’s
instructions. In brief, ribosomal RNA was depleted from total
RNA using Ribo-Zero magnetic beads, and then, the ribosomal
RNA-depleted RNA was purified and fragmented. Random primer
tailed with Illumina adaptor was used to perform reverse tran-
scription to get cDNA library. Adaptor sequence was added to the
other end of cDNA library with a Terminal-Tagging step. cDNA
library was amplified with Illumina primers provided with this kit.
The product was size selected (350–500 bp) from 2% agarose
E-gels (Invitrogen) and sequenced in 1 lane per sample on Illumina’s
HiSeq 2000 platform.
Analysis
The sequenced 101 × 2 pair-end fragments were mapped against
the human RefSeq transcriptome using TopHat v2.0.8 (http://
tophat.cbcb.umd.edu). Quantitation of expression levels was
computed with CuffLinks v2.0.2 (http://cufflinks.cbcb.umd.edu).
We excluded genes with low expression in both cases and controls
(FPKM < 1) to avoid numerical fluctuations by small numbers and
retained ~12,000 highly expressed genes in this study (with “OK”
status from Cufflinks calculation), which were likely more relevant
to the physiology of this particular tissue type. We also retrieved the
medical and neuropathology records of these patients and found
that three patients had no documented medication history related to
ASD. The other three patients took medications to correct their
ASD-related behaviors; however, the potential drug targets (deter-
mined by microarray study upon drug exposure or literature cura-
tion, data not shown) were not present in our module. Therefore,
medication cannot fully explain the dys-regulated genes in our
module.
Human subjects
This study was exempt from Stanford IRB review since only post-
mortem brain tissues from de-identified and deceased individuals
were examined in this study. Brain tissues/DNA extracts were
obtained from ATP and NICHD, where informed consent was
obtained from all subjects. The experiments conformed to the prin-
ciples set out in the WMA Declaration of Helsinki and the Depart-
ment of Health and Human Services Belmont Report.
Data availability
RNA-sequencing data are deposited in GEO with the accession iden-
tifiers: GSE62098 and GSE63513. DNA-sequencing data are depos-
ited in SRA with the accession identifiers SRP050187.
Supplementary information for this article is available online:
http://msb.embopress.org
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